Literature DB >> 21628926

Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome.

Hisamitsu Miyaaki1, Tatsuki Ichikawa, Naota Taura, Satoshi Miuma, Hidetaka Shibata, Hajime Isomoto, Fuminao Takeshima, Kazuhiko Nakao.   

Abstract

OBJECTIVE: We evaluated patients with chronic hepatitis C (CHC) and compared the clinical and pathological features of steatosis and metabolic syndrome to identify the risk factors for CHC with severe fibrosis.
METHODS: One hundred seventy-one patients with biopsy-confirmed CHC were included in the study: 90 males and 81 females, age 56.2 ± 12.8 years; 46 with obesity (BMI≥25 kg/m(2)); 51 with hypertension; 36 with type 2 diabetes mellitus; and 20 with hypertriglyceridemia.
RESULTS: Steatosis was detected in 79 patients (46%); 92 patients (54%) showed no steatosis. Seventy-four patients (43%) showed mild fibrosis and 97 patients (56%) showed severe fibrosis. The variables that were significantly associated with steatosis were obesity [odds ratio 2.160 (1.010-4.727), p=0.046] and type 2 diabetes [odds ratio 3.667 (1.559-8.430), p=0.027]. The variables that were significantly associated with severe fibrosis were older age [odds ratio 2.675 (1.309-5.464), p=0.007], obesity [odds ratio 2.156 (1.006-4.619), p=0.048] and type 2 diabetes [odds ratio 8.739 (2.845-26.846), p=0.0002]. Nagasaki (N) score (the total number of specific risk factors, namely an older age, obesity, and type 2 diabetes) was higher in the severe fibrosis group than in the mild fibrosis group (mild fibrosis: severe fibrosis=1.48 ± 1.14 vs.2.66 ± 94, p<0.001).
CONCLUSION: Metabolic syndrome factors, including obesity and diabetes, play a critical role in the pathogenesis of fibrosis in CHC. The N score was therefore found to be a significant predictor of severe fibrosis in CHC.

Entities:  

Mesh:

Year:  2011        PMID: 21628926     DOI: 10.2169/internalmedicine.50.4447

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

1.  Reproductive status is associated with the severity of fibrosis in women with hepatitis C.

Authors:  Erica Villa; Ranka Vukotic; Calogero Cammà; Salvatore Petta; Alfredo Di Leo; Stefano Gitto; Elena Turola; Aimilia Karampatou; Luisa Losi; Veronica Bernabucci; Annamaria Cenci; Simonetta Tagliavini; Enrica Baraldi; Nicola De Maria; Roberta Gelmini; Elena Bertolini; Maria Rendina; Antonio Francavilla
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

2.  Diabetes mellitus is a significant risk factor for the development of liver cirrhosis in chronic hepatitis C patients.

Authors:  Xu Li; Yang Gao; Hongqin Xu; Jie Hou; Pujun Gao
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

Review 3.  Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review.

Authors:  Anne-Claire Desbois; Patrice Cacoub
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

4.  Pooled Analysis of the Associations between Body Mass Index, Total Cholesterol, and Liver Cancer-related Mortality in Japan

Authors:  Shigekazu Ukawa; Akiko Tamakoshi; Yoshitaka Murakami; Yutaka Kiyohara; Michiko Yamada; Masato Nagai; Atsushi Satoh; Katsuyuki Miura; Hirotsugu Ueshima; Tomonori Okamura
Journal:  Asian Pac J Cancer Prev       Date:  2018-08-24

5.  Long-term impact of certain coexisting extrahepatic unisystem and multisystem manifestations on trends in incidence of liver cirrhosis in treatment-naïve patients with chronic hepatitis C: A nested case-control study.

Authors:  Chun-Hsiang Wang; Shih-Fang Ou; Yuan-Tsung Tseng
Journal:  Medicine (Baltimore)       Date:  2022-07-22       Impact factor: 1.817

6.  Possible unrecognised liver injury is associated with mortality in critically ill COVID-19 patients.

Authors:  Mario Romero-Cristóbal; Ana Clemente-Sánchez; Patricia Piñeiro; Jamil Cedeño; Laura Rayón; Julia Del Río; Clara Ramos; Diego-Andrés Hernández; Miguel Cova; Aranzazu Caballero; Ignacio Garutti; Pablo García-Olivares; Javier Hortal; Jose-Eugenio Guerrero; Rita García; Rafael Bañares; Diego Rincón
Journal:  Therap Adv Gastroenterol       Date:  2021-06-14       Impact factor: 4.409

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.